Literature DB >> 17353396

Changes in PDE4D isoforms in the hippocampus of a patient with advanced Alzheimer disease.

Craig S McLachlan, Melissa L Chen, Clare N Lynex, Denise L M Goh, Sydney Brenner, Stacey K H Tay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17353396     DOI： 10.1001/archneur.64.3.456

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  11 in total

Review 1.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

Review 2.  Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder.

Authors:  Rui-Ting Wen; Fang-Fang Zhang; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2018-04-16       Impact factor: 4.530

Review 3.  Phosphodiesterases as therapeutic targets for Alzheimer's disease.

Authors:  Ana García-Osta; Mar Cuadrado-Tejedor; Carolina García-Barroso; Julen Oyarzábal; Rafael Franco
Journal:  ACS Chem Neurosci       Date:  2012-10-01       Impact factor: 4.418

4.  Brain region-specific decrease in the activity and expression of protein kinase A in the frontal cortex of regressive autism.

Authors:  Lina Ji; Ved Chauhan; Michael J Flory; Abha Chauhan
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

Review 5.  Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.

Authors:  Eric P Knott; Mazen Assi; Sudheendra N R Rao; Mousumi Ghosh; Damien D Pearse
Journal:  Int J Mol Sci       Date:  2017-03-24       Impact factor: 5.923

6.  Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease.

Authors:  Roberta Ricciarelli; Chiara Brullo; Jos Prickaerts; Ottavio Arancio; Carla Villa; Claudia Rebosio; Elisa Calcagno; Matilde Balbi; Britt T J van Hagen; Elentina K Argyrousi; Hong Zhang; Maria Adelaide Pronzato; Olga Bruno; Ernesto Fedele
Journal:  Sci Rep       Date:  2017-04-12       Impact factor: 4.379

Review 7.  Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches.

Authors:  Amy J Tibbo; Gonzalo S Tejeda; George S Baillie
Journal:  Biochem Soc Trans       Date:  2019-10-31       Impact factor: 5.407

Review 8.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

9.  Amyloid β-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition.

Authors:  Fernando Bartolome; Macarena de la Cueva; Consuelo Pascual; Desiree Antequera; Tamara Fernandez; Carmen Gil; Ana Martinez; Eva Carro
Journal:  Alzheimers Res Ther       Date:  2018-02-20       Impact factor: 6.982

10.  Phosphodiesterase PDE4D Is Decreased in Frontal Cortex of Aged Rats and Positively Correlated With Working Memory Performance and Inversely Correlated With PKA Phosphorylation of Tau.

Authors:  Shannon N Leslie; Dibyadeep Datta; Kyle R Christensen; Christopher H van Dyck; Amy F T Arnsten; Angus C Nairn
Journal:  Front Aging Neurosci       Date:  2020-10-28       Impact factor: 5.750
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.